Home・Список акций・Kura Oncology Inc

Kura Oncology Inc

Закрыт

СекторЗдравоохранение

9.51 3.03

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

9.49

Макс.

9.58

Ключевые показатели
By Trading Economics
Доход	7.7M -73M
Продажи	929K 18M
Прибыль на акцию	-0.828
Рентабельность продаж	-401.495
Сотрудники	260
EBITDA	13M -73M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+193.73% upside

Дивиденды
By Acuity
Следующий отчет о доходах	12 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-28M 816M
Предыдущая цена открытия	6.48
Предыдущая цена закрытия	9.51

Новостные настроения

By Acuity

37%

63%

111 / 340 Рейтинг в Healthcare

Kura Oncology Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

7 авг. 2026 г., 23:36 UTC

Kura Oncology Inc shares are lower in after-market hours, retracing from earlier gains. The stock remains below its 20-day moving average.

6 авг. 2026 г., 21:02 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close amid positive sentiment in the broader market.

5 авг. 2026 г., 19:26 UTC

News

Kura Oncology Inc shares are lower today amid ongoing market volatility. The company will report second-quarter 2026 results after the market close on August 12.

4 авг. 2026 г., 19:36 UTC

Kura Oncology Inc shares are higher today, continuing an upward trend since Monday. Broader market reactions follow a decline in U.S. core factory orders.

3 авг. 2026 г., 23:01 UTC

Kura Oncology Inc. shares are higher in after-market trading, reflecting notable gains since Monday's close, despite no specific news to explain the increase.

31 июл. 2026 г., 21:01 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable rise since Friday's close despite remaining below the 20-day moving average.

30 июл. 2026 г., 19:49 UTC

Kura Oncology Inc shares are higher Thursday, continuing a recent upward trend despite no specific news. The stock has rebounded from earlier session lows.

29 июл. 2026 г., 19:22 UTC

Macro Event

Kura Oncology shares are lower, extending a six-session decline amid market volatility following the Federal Reserve's interest rate decision.

28 июл. 2026 г., 20:03 UTC

Event

Kura Oncology shares are lower despite positive Phase 1a trial results for darlifarnib plus cabozantinib, reflecting broader market pressures.

27 июл. 2026 г., 20:07 UTC

Social Media

News

Event

Kura Oncology shares are lower as the company reported Phase 1a results from its FIT-001 trial, showing a 33% to 50% response rate.

22 июл. 2026 г., 22:01 UTC

Kura Oncology Inc. shares are lower in after-market trading, reflecting unusual volatility amid broader market fluctuations from rising crude oil prices and geopolitical tensions.

21 июл. 2026 г., 19:36 UTC

Kura Oncology shares are higher Tuesday, amid positive market sentiment despite an earlier pullback. The stock remains below its 20-day moving average.

20 июл. 2026 г., 18:36 UTC

Kura Oncology shares are lower today, pulling back from earlier gains amid a broader market decline linked to rising Treasury yields and geopolitical tensions.

Сравнение c конкурентами

Изменение цены

Kura Oncology Inc Прогноз

Целевая цена

By TipRanks

193.73% рост

Прогноз на 12 месяцев

Средняя 28.11 USD 193.73%

Максимум 40 USD

Минимум 15 USD

Основано на мнении 10 аналитиков Wall Street, спрогнозировавших целевые цены для Kura Oncology Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

10 ratings

Покупка

Удержание

Продажа

Основано на мнении 10 аналитиков, присваивавших рейтинги акциям Kura Oncology Inc – Данные за последние 3 месяца.

Настроения

By Acuity

111 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.